Director, Duke Prostate Center
James H. Semans, MD, Professor of Surgery
Address
DUMC 3707
Durham, NC 27710
Appointment Telephone
919-668-8108
Office Telephone
919-684-5057
Fax Telephone
919-684-8794
Clinical Interests
Minimally invasive nerve-sparing radical prostatectomy, treatment of PSA-only or biochemical recurrence of prostate cancer, prostate cancer in African Americans, multidisciplinary management of prostate cancer, clinical trials in prostate disease, elevated PSA and screening, prostate cancer and outcomes/database research, elevated PSA and prostate cancer screening issues, active surveillance in early stage prostate cancer
This faculty member (or a member of their immediate family) has a working relationship (i.e. consulting, research, and/or educational services) with the companies listed below. These relations have been reported to the health system leadership and, when appropriate, management plans are in place to address potential conflicts.
Representative Publications
Boorjian, SA; Eastham, JA; Graefen, M; Guillonneau, B; Karnes, RJ; Moul, JW; Schaeffer, EM; Stief, C; Zorn, KC. A critical analysis of the long-term impact of radical prostatectomy on cancer control and function outcomes. European Urology. 2012;61:664-675.
(2012)
Abstract
George, D; Moul, JW. Emerging treatment options for patients with castration-resistant prostate cancer. The Prostate. 2012;72:338-349.
(2012)
Abstract
Loeb, S; Carter, HB; Catalona, WJ; Moul, JW; Schroder, FH. Baseline prostate-specific antigen testing at a young age. European Urology. 2012;61:1-7.
(2012)
Abstract
Moul, JW. Prostate cancer: making the switch from LHRH antagonist to LHRH agonist. Nature Reviews Urology. 2012;9:125-126.
(2012)
Abstract
Moul, JW; Dawson, N. Quality of life associated with treatment of castration-resistant prostate cancer: a review of the literature. Cancer Investigation. 2012;30:1-12.
(2012)
Abstract
Schroeck, FR; Krupski, TL; Stewart, SB; Bañez, LL; Gerber, L; Albala, DM; Moul, JW. Pretreatment expectations of patients undergoing robotic assisted laparoscopic or open retropubic radical prostatectomy. Journal of Urology. 2012;187:894-898.
(2012)
Abstract
Stewart, SB; Bañez, LL; Robertson, CN; Freedland, SJ; Polascik, TJ; Xie, D; Koontz, BF; Vujaskovic, Z; Lee, WR; Armstrong, AJ; Febbo, PG; George, DJ; Moul, JW. Utilization trends at a multidisciplinary prostate cancer clinic: initial 5-year experience from the Duke Prostate Center. Journal of Urology. 2012;187:103-108.
(2012)
Abstract
Tang, P; Du, W; Xie, K; Fu, J; Chen, H; Yang, W; Moul, JW. Characteristics of baseline PSA and PSA velocity in young men without prostate cancer: Racial differences. The Prostate. 2012;72:173-180.
(2012)
Abstract
Tsivian, M; Moreira, DM; Sun, L; Mouraviev, V; Kimura, M; Moul, JW; Polascik, TJ. Biopsy accuracy in identifying unilateral prostate cancer depends on prostate weight. Urologic Oncology: seminars and original investigations. 2012;30:21-25.
(2012)
Abstract
Wattson, DA; Chen, MH; Moul, JW; Moran, BJ; Dosoretz, DE; Robertson, CN; Polascik, TJ; Braccioforte, MH; Salenius, SA; D'Amico, AV. The number of high-risk factors and the risk of prostate cancer-specific mortality after brachytherapy: implications for treatment selection. International Journal of Radiation: Oncology - Biology - Physics. 2012;82:e773-e779.
(2012)
Abstract
Arvold, ND; Chen, MH; Moul, JW; Moran, BJ; Dosoretz, DE; Bañez, LL; Katin, MJ; Braccioforte, MH; D'Amico, AV. Risk of death from prostate cancer after radical prostatectomy or brachytherapy in men with low or intermediate risk disease. Journal of Urology. 2011;186:91-96.
(2011)
Abstract
Chu, DI; De Nunzio, C; Gerber, L; Thomas, JA; Calloway, EE; Albisinni, S; Senocak, C; McKeever, MG; Moreira, DM; Tubaro, A; Moul, JW; Freedland, SJ; Bañez, LL. Predictive value of digital rectal examination for prostate cancer detection is modified by obesity. Prostate Cancer and Prostatic Diseases. 2011;14:346-353.
(2011)
Abstract
Cotter, SE; Chen, MH; Moul, JW; Lee, WR; Koontz, BF; Anscher, MS; Robertson, CN; Walther, PJ; Polascik, TJ; D'Amico, AV. Salvage radiation in men after prostate-specific antigen failure and the risk of death. Cancer. 2011;117:3925-3932.
(2011)
Abstract
Crawford, ED; Moul, JW; Rove, KO; Pettaway, CA; Lamerato, LE; Hughes, A. Prostate-specific antigen 1.5-4.0 ng/mL: a diagnostic challenge and danger zone. BJU International. 2011;108:1743-1749.
(2011)
Abstract
Dreicer, R; Bajorin, DF; McLeod, DG; Petrylak, DP; Moul, JW. New data, new paradigms for treating prostate cancer patients--VI: novel hormonal therapy approaches. Urology. 2011;78:S494-S498.
(2011)
Abstract
Fu, Q; Moul, JW; Sun, L. Contemporary radical prostatectomy. Prostate Cancer. 2011;2011:645030.
(2011)
Abstract
Moul, JW; Evans, CP; Gomella, LG; Roach, M; Dreicer, R. Traditional approaches to androgen deprivation therapy. Urology. 2011;78:S485-S493.
(2011)
Abstract
Reed, SD; Scales, CD; Stewart, SB; Sun, J; Moul, JW; Schulman, KA; Xu, J. Effects of family history and genetic polymorphism on the cost-effectiveness of chemoprevention with finasteride for prostate cancer. Journal of Urology. 2011;185:841-847.
(2011)
Abstract
Tang, P; Sun, L; Uhlman, MA; Robertson, CN; Polascik, TJ; Moul, JW. Prostate-specific antigen velocity based risk-adapted discontinuation of prostate cancer screening in elderly men. BJU International. 2011;108:44-48.
(2011)
Abstract
Ali, A; Furusato, B; Ts'o, PO; Lum, ZP; Elsamanoudi, S; Mohamed, A; Srivastava, S; Moul, JW; Brassell, SA; Sesterhenn, IA; McLeod, DG. Assessment of circulating tumor cells (CTCs) in prostate cancer patients with low-volume tumors. Pathology International. 2010;60:667-672.
(2010)
Abstract
Caire, AA; Sun, L; Lack, BD; Lum, K; Tang, P; Stackhouse, DA; Robertson, CN; Mouraviev, V; Polascik, TJ; Albala, DM; Moul, JW. Predicting non-organ-confined prostate cancer in men diagnosed after 2000. Prostate Cancer and Prostatic Diseases. 2010;13:248-251.
(2010)
Abstract
Caire, AA; Sun, L; Polascik, TJ; Albala, DM; Moul, JW. Obese African-Americans with prostate cancer (T1c and a prostate-specific antigen, PSA, level of <10 ng/mL) have higher-risk pathological features and a greater risk of PSA recurrence than non-African-Americans. BJU International. 2010;106:1157-1160.
(2010)
Abstract
Caire, AA; Sun, L; Robertson, CN; Polascik, TJ; Maloney, KE; George, DJ; Price, MM; Stackhouse, DA; Lack, BD; Albala, DM; Moul, JW. Public survey and survival data do not support recommendations to discontinue prostate-specific antigen screening in men at age 75. Urology. 2010;75:1122-1127.
(2010)
Abstract
Caso, JR; Mouraviev, V; Tsivian, M; Polascik, TJ; Moul, JW. Prostate cancer: an evolving paradigm. Journal of Endourology. 2010;24:805-809.
(2010)
Abstract
Caso, JR; Tsivian, M; Mouraviev, V; Polascik, TJ; Moul, JW. Pathological T2 sub-divisions as a prognostic factor in the biochemical recurrence of prostate cancer. BJU International. 2010;106:1623-1627.
(2010)
Abstract
D'Amico, AV; Chen, MH; Sun, L; Lee, WR; Mouraviev, V; Robertson, CN; Walther, PJ; Polascik, TJ; Albala, DM; Moul, JW. Adjuvant versus salvage radiation therapy for prostate cancer and the risk of death. BJU International. 2010;106:1618-1622.
(2010)
Abstract
Droz, JP; Balducci, L; Bolla, M; Emberton, M; Fitzpatrick, JM; Joniau, S; Kattan, MW; Monfardini, S; Moul, JW; Naeim, A; van Poppel, H; Saad, F; Sternberg, CN. Background for the proposal of SIOG guidelines for the management of prostate cancer in senior adults. Critical Reviews in Oncology Hematology. 2010;73:68-91.
(2010)
Abstract
Droz, JP; Balducci, L; Bolla, M; Emberton, M; Fitzpatrick, JM; Joniau, S; Kattan, MW; Monfardini, S; Moul, JW; Naeim, A; van Poppel, H; Saad, F; Sternberg, CN. Management of prostate cancer in older men: recommendations of a working group of the International Society of Geriatric Oncology. BJU International. 2010;106:462-469.
(2010)
Abstract
Jayachandran, J; Schroeck, F; Sun, L; Gerber, L; Moreira, DM; Moul, JW; Freedland, SJ. The Shared Equal Access Regional Cancer Hospital (SEARCH) nomogram for risk stratification in intermediate risk group of men with prostate cancer: validation in the Duke Prostate Center database. BJU International. 2010;105:180-184.
(2010)
Abstract
Moreira, DM; Presti, JC; Aronson, WJ; Terris, MK; Kane, CJ; Amling, CL; Sun, LL; Moul, JW; Freedland, SJ. The effect of race on the discriminatory accuracy of models to predict biochemical recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center databases. Prostate Cancer and Prostatic Diseases. 2010;13:87-93.
(2010)
Abstract
Moul, JW. Radiotherapy: Secondary malignancies after prostate cancer treatment. Nature Reviews. Clinical Oncology. 2010;7:249-250.
(2010)
Abstract
Moul, JW; Tang, P; Sun, L. Editorial comment on: Development of a new method for monitoring prostate-specific antigen changes in men with localised prostate cancer: a comparison of observational cohorts. European Urology. 2010;57:452.
(2010)
Abstract
Schroeck, FR; Kattan, MW; Moul, JW; Aronson, WJ; Presti, JC; Terris, MK; Kane, CJ; Amling, CL; Sun, L; Freedland, SJ. Re-calibration and external validation of an existing nomogram to predict aggressive recurrences after radical prostatectomy. BJU International. 2010;105:1654-1659.
(2010)
Abstract
Tang, P; Sun, L; Uhlman, MA; Polascik, TJ; Freedland, SJ; Moul, JW. Baseline PSA as a predictor of prostate cancer-specific mortality over the past 2 decades: Duke University experience. Cancer. 2010;116:4711-4717.
(2010)
Abstract
Tang, P; Sun, L; Uhlman, MA; Robertson, CN; Polascik, TJ; Albala, DM; Donatucci, CF; Moul, JW. Initial prostate specific antigen 1.5 ng/ml or greater in men 50 years old or younger predicts higher prostate cancer risk. Journal of Urology. 2010;183:946-950.
(2010)
Abstract
Uhlman, MA; Sun, L; Stackhouse, DA; Caire, AA; Polascik, TJ; Robertson, CN; Madden, J; Vollmer, R; Albala, DM; Moul, JW. Tumor volume, tumor percentage involvement, or prostate volume: which is predictive of prostate-specific antigen recurrence?. Urology. 2010;75:460-466.
(2010)
Abstract
Uhlman, MA; Sun, L; Stackhouse, DA; Polascik, TJ; Mouraviev, V; Robertson, CN; Albala, DM; Moul, JW. Tumor percent involvement predicts prostate specific antigen recurrence after radical prostatectomy only in men with smaller prostate. Journal of Urology. 2010;183:997-1001.
(2010)
Abstract
Bañez, LL; Blake, GW; McLeod, DG; Crawford, ED; Moul, JW. Combined low-dose flutamide plus finasteride vs low-dose flutamide monotherapy for recurrent prostate cancer: a comparative analysis of two phase II trials with a long-term follow-up. BJU International. 2009;104:310-314.
(2009)
Abstract
Bañez, LL; Sun, L; Trock, BJ; Han, M; Partin, AW; Aronson, WJ; Terris, MK; Presti, JC; Kane, CJ; Amling, CL; Moul, JW; Freedland, SJ. Body mass index and prostate specific antigen as predictors of adverse pathology and biochemical recurrence after prostatectomy. Journal of Urology. 2009;182:491-496.
(2009)
Abstract
Caire, AA; Sun, L; Ode, O; Stackhouse, DA; Maloney, K; Donatucci, C; Mouraviev, V; Polascik, TJ; Robertson, CN; Albala, DM; Moul, JW. Delayed prostate-specific antigen recurrence after radical prostatectomy: how to identify and what are their clinical outcomes?. Urology. 2009;74:643-647.
(2009)
Abstract
Chen, VH; Mouraviev, V; Mayes, JM; Sun, L; Madden, JF; Moul, JW; Polascik, TJ. Utility of a 3-dimensional transrectal ultrasound-guided prostate biopsy system for prostate cancer detection. Technology in Cancer Research and Treatment. 2009;8:99-104.
(2009)
Abstract
Chino, J; Schroeck, FR; Sun, L; Lee, WR; Albala, DM; Moul, JW; Koontz, BF. Robot-assisted laparoscopic prostatectomy is not associated with early postoperative radiation therapy. BJU International. 2009;104:1496-1500.
(2009)
Abstract
D'Alonzo, RC; Gan, TJ; Moul, JW; Albala, DM; Polascik, TJ; Robertson, CN; Sun, L; Dahm, P; Habib, AS. A retrospective comparison of anesthetic management of robot-assisted laparoscopic radical prostatectomy versus radical retropubic prostatectomy. Journal of Clinical Anesthesia. 2009;21:322-328.
(2009)
Abstract
Freedland, SJ; Bañez, LL; Sun, LL; Fitzsimons, NJ; Moul, JW. Obese men have higher-grade and larger tumors: an analysis of the duke prostate center database. Prostate Cancer and Prostatic Diseases. 2009;12:259-263.
(2009)
Abstract
Habib, AS; Polascik, TJ; Weizer, AZ; White, WD; Moul, JW; ElGasim, MA; Gan, TJ. Lidocaine patch for postoperative analgesia after radical retropubic prostatectomy. Anesthesia and Analgesia. 2009;108:1950-1953.
(2009)
Abstract
Moul, JW. Innovations in urology from military medicine. Urologic Oncology: seminars and original investigations. 2009;27:551-552.
(2009)
Abstract
Moul, JW. Post-radical prostatectomy management options for positive surgical margins: argument for observation. Urologic Oncology: seminars and original investigations. 2009;27:92-96.
(2009)
Abstract
Moul, JW. Report from Durham. Prostate Cancer and Prostatic Diseases. 2009;12:209-210.
(2009)
Abstract
Moul, JW. Twenty years of controversy surrounding combined androgen blockade for advanced prostate cancer. Cancer. 2009;115:3376-3378.
(2009)
Abstract
Moul, JW. Twenty-five year evolution of medical hormonal therapy for prostate cancer. BJU International. 2009;103:145-146.
(2009)
Abstract
Moul, JW. Will the global economic downturn affect prostate cancer care? Pelvic lymphadenectomy as an example. European Urology. 2009;55:1266-1268.
(2009)
Abstract
Moul, JW; Mouraviev, V; Sun, L; Schroeck, FR; Polascik, TJ. Prostate cancer: the new landscape. Current Opinion in Urology. 2009;19:154-160.
(2009)
Abstract
Nguyen, PL; Chen, MH; Catalona, WJ; Moul, JW; Sun, L; D'Amico, AV. Predicting prostate cancer mortality among men with intermediate to high-risk disease and multiple unfavorable risk factors. International Journal of Radiation: Oncology - Biology - Physics. 2009;73:659-664.
(2009)
Abstract
Polascik, TJ; Mayes, JM; Schroeck, FR; Sun, L; Madden, JF; Moul, JW; Mouraviev, V. Patient selection for hemiablative focal therapy of prostate cancer: variables predictive of tumor unilaterality based upon radical prostatectomy. Cancer. 2009;115:2104-2110.
(2009)
Abstract
Stackhouse, DA; Sun, L; Schroeck, FR; Jayachandran, J; Caire, AA; Acholo, CO; Robertson, CN; Albala, DM; Polascik, TJ; Donatucci, CF; Maloney, KE; Moul, JW. Factors predicting prostatic biopsy Gleason sum under grading. Journal of Urology. 2009;182:118-122.
(2009)
Abstract
Sun, L; Caire, AA; Robertson, CN; George, DJ; Polascik, TJ; Maloney, KE; Walther, PJ; Stackhouse, DA; Lack, BD; Albala, DM; Moul, JW. Men older than 70 years have higher risk prostate cancer and poorer survival in the early and late prostate specific antigen eras. Journal of Urology. 2009;182:2242-2248.
(2009)
Abstract
Tsivian, M; Sun, L; Mouraviev, V; Madden, JF; Mayes, JM; Moul, JW; Polascik, TJ. Changes in Gleason score grading and their effect in predicting outcome after radical prostatectomy. Urology. 2009;74:1090-1093.
(2009)
Abstract
Xu, DD; Sun, SD; Wang, F; Sun, L; Stackhouse, D; Polascik, T; Albala, DM; Moul, JW; Caire, A; Robertson, CN. Effect of age and pathologic Gleason score on PSA recurrence: analysis of 2911 patients undergoing radical prostatectomy. Urology. 2009;74:654-658.
(2009)
Abstract
Demark-Wahnefried, W; Polascik, TJ; George, SL; Switzer, BR; Madden, JF; Ruffin, MT; Snyder, DC; Owzar, K; Hars, V; Albala, DM; Walther, PJ; Robertson, CN; Moul, JW; Dunn, BK; Brenner, D; Minasian, L; Stella, P; Vollmer, RT. Flaxseed supplementation (not dietary fat restriction) reduces prostate cancer proliferation rates in men presurgery. Cancer Epidemiology, Biomarkers and Prevention. 2008;17:3577-3587.
(2008)
Abstract
Freedland, SJ; Sun, L; Kane, CJ; Presti, JC; Terris, MK; Amling, CL; Moul, JW; Aronson, WJ. Obesity and oncological outcome after radical prostatectomy: impact of prostate-specific antigen-based prostate cancer screening: results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center databases. BJU International. 2008;102:969-974.
(2008)
Abstract
Habib, AS; White, WD; El Gasim, MA; Saleh, G; Polascik, TJ; Moul, JW; Gan, TJ. Transdermal nicotine for analgesia after radical retropubic prostatectomy. Anesthesia and Analgesia. 2008;107:999-1004.
(2008)
Abstract
Isariyawongse, BK; Sun, L; Bañez, LL; Robertson, C; Polascik, TJ; Maloney, K; Donatucci, C; Albala, D; Mouraviev, V; Madden, JF; Moul, JW. Significant discrepancies between diagnostic and pathologic Gleason sums in prostate cancer: the predictive role of age and prostate-specific antigen. Urology. 2008;72:882-886.
(2008)
Abstract
Moul, JW. Are we overtreating prostate cancer?. Journal of Urology. 2008;180:2299-2300.
(2008)
Abstract
Moul, JW. Point: radical prostatectomy is the treatment of choice for high-risk prostate cancer patients. Brachytherapy. 2008;7:277-279.
(2008)
Abstract
Moul, JW. Report from Durham. Prostate Cancer and Prostatic Diseases. 2008;11:1.
(2008)
Abstract
Moul, JW. Report from Durham. Prostate Cancer and Prostatic Diseases. 2008;11:211.
(2008)
Abstract
Moul, JW. Words of wisdom. Re: obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. European Urology. 2008;54:232-233.
(2008)
Abstract
Moul, JW; Wu, H; Sun, L; McLeod, DG; Amling, C; Donahue, T; Kusuda, L; Sexton, W; O'Reilly, K; Hernandez, J; Chung, A; Soderdahl, D. Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. Journal of Urology. 2008;179:S53-S59.
(2008)
Abstract
Mouraviev, V; Broadwater, G; Sun, L; Mayes, JM; Moul, JW; Polascik, TJ. Can prostate-specific antigen and prostate-specific antigen velocity be used for prostate cancer screening in men older than 70 years?. Urology. 2008;71:1020-1023.
(2008)
Abstract
Polascik, TJ; Mayes, JM; Sun, L; Madden, JF; Moul, JW; Mouraviev, V. Pathologic stage T2a and T2b prostate cancer in the recent prostate-specific antigen era: implications for unilateral ablative therapy. The Prostate. 2008;68:1380-1386.
(2008)
Abstract
Rampersaud, EN; Sun, L; Moul, JW; Madden, J; Freedland, SJ. Percent tumor involvement and risk of biochemical progression after radical prostatectomy. Journal of Urology. 2008;180:571-576.
(2008)
Abstract
Scales, CD; Antonelli, J; Curtis, LH; Schulman, KA; Moul, JW. Prostate-specific antigen screening among young men in the United States. Cancer. 2008;113:1315-1323.
(2008)
Abstract
Schroeck, FR; Donatucci, CF; Smathers, EC; Sun, L; Albala, DM; Polascik, TJ; Moul, JW; Krupski, TL. Defining potency: a comparison of the International Index of Erectile Function short version and the Expanded Prostate Cancer Index Composite. Cancer. 2008;113:2687-2694.
(2008)
Abstract
Schroeck, FR; Krupski, TL; Sun, L; Albala, DM; Price, MM; Polascik, TJ; Robertson, CN; Tewari, AK; Moul, JW. Satisfaction and regret after open retropubic or robot-assisted laparoscopic radical prostatectomy. European Urology. 2008;54:785-793.
(2008)
Abstract
Schroeck, FR; Sun, L; Freedland, SJ; Albala, DM; Mouraviev, V; Polascik, TJ; Moul, JW. Comparison of prostate-specific antigen recurrence-free survival in a contemporary cohort of patients undergoing either radical retropubic or robot-assisted laparoscopic radical prostatectomy. BJU International. 2008;102:28-32.
(2008)
Abstract
Schroeck, FR; Sun, L; Freedland, SJ; Jayachandran, J; Robertson, CN; Moul, JW. Race and prostate weight as independent predictors for biochemical recurrence after radical prostatectomy. Prostate Cancer and Prostatic Diseases. 2008;11:371-376.
(2008)
Abstract
Schroeck, FR; de Sousa, CA; Kalman, RA; Kalia, MS; Pierre, SA; Haleblian, GE; Sun, L; Moul, JW; Albala, DM. Trainees do not negatively impact the institutional learning curve for robotic prostatectomy as characterized by operative time, estimated blood loss, and positive surgical margin rate. Urology. 2008;71:597-601.
(2008)
Abstract
Weinrich, SP; Seger, RE; Rao, GS; Chan, EC; Hamm, RM; Godley, PA; Moul, JW; Powell, IJ; Chodak, GW; Taylor, KL; Weinrich, MC. A decision aid for teaching limitations of prostate cancer screening. Journal of National Black Nurses' Association. 2008;19:1-11.
(2008)
Abstract
Whittemore, DE; Hick, EJ; Carter, MR; Moul, JW; Miranda-Sousa, AJ; Sexton, WJ. Significance of tertiary Gleason pattern 5 in Gleason score 7 radical prostatectomy specimens. Journal of Urology. 2008;179:516-522.
(2008)
Abstract
Bañez, LL; Hamilton, RJ; Partin, AW; Vollmer, RT; Sun, L; Rodriguez, C; Wang, Y; Terris, MK; Aronson, WJ; Presti, JC; Kane, CJ; Amling, CL; Moul, JW; Freedland, SJ. Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. JAMA: Journal of the American Medical Association. 2007;298:2275-2280.
(2007)
Abstract
Burnett, AL; Aus, G; Canby-Hagino, ED; Cookson, MS; D'Amico, AV; Dmochowski, RR; Eton, DT; Forman, JD; Goldenberg, SL; Hernandez, J; Higano, CS; Kraus, S; Liebert, M; Moul, JW; Tangen, C; Thrasher, JB; Thompson, I; American Urological Association Prostate Cancer Guideline Update Panel. Erectile function outcome reporting after clinically localized prostate cancer treatment. Journal of Urology. 2007;178:597-601.
(2007)
Abstract
Cookson, MS; Aus, G; Burnett, AL; Canby-Hagino, ED; D'Amico, AV; Dmochowski, RR; Eton, DT; Forman, JD; Goldenberg, SL; Hernandez, J; Higano, CS; Kraus, SR; Moul, JW; Tangen, C; Thrasher, JB; Thompson, I. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. Journal of Urology. 2007;177:540-545.
(2007)
Abstract
D'Amico, AV; Chen, MH; Catalona, WJ; Sun, L; Roehl, KA; Moul, JW. Prostate cancer-specific mortality after radical prostatectomy or external beam radiation therapy in men with 1 or more high-risk factors. Cancer. 2007;110:56-61.
(2007)
Abstract
Fitzsimons, NJ; Sun, L; Moul, JW. Medical technologies for the diagnosis of prostate cancer. Expert Review of Medical Devices. 2007;4:227-239.
(2007)
Abstract
Fitzsimons, NJ; Sun, LL; Dahm, P; Moul, JW; Madden, J; Gan, TJ; Freedland, SJ. A single-institution comparison between radical perineal and radical retropubic prostatectomy on perioperative and pathological outcomes for obese men: an analysis of the Duke Prostate Center database. Urology. 2007;70:1146-1151.
(2007)
Abstract
Freedland, SJ; Moul, JW. Prostate specific antigen recurrence after definitive therapy. Journal of Urology. 2007;177:1985-1991.
(2007)
Abstract
Moul, JW. Timely diagnosis of testicular cancer. Urologic Clinics of North America. 2007;34:109-117.
(2007)
Abstract
Moul, JW; Bañez, LL; Freedland, SJ. Rising PSA in nonmetastatic prostate cancer. Oncology. 2007;21:1436-1445.
(2007)
Abstract
Moul, JW; Sun, L; Hotaling, JM; Fitzsimons, NJ; Polascik, TJ; Robertson, CN; Dahm, P; Anscher, MS; Mouraviev, V; Pappas, PA; Albala, DM. Age adjusted prostate specific antigen and prostate specific antigen velocity cut points in prostate cancer screening. Journal of Urology. 2007;177:499-503.
(2007)
Abstract
Mouraviev, V; Mayes, JM; Sun, L; Madden, JF; Moul, JW; Polascik, TJ. Prostate cancer laterality as a rationale of focal ablative therapy for the treatment of clinically localized prostate cancer. Cancer. 2007;110:906-910.
(2007)
Abstract
Mouraviev, V; Nosnik, I; Sun, L; Robertson, CN; Walther, P; Albala, D; Moul, JW; Polascik, TJ. Financial comparative analysis of minimally invasive surgery to open surgery for localized prostate cancer: a single-institution experience. Urology. 2007;69:311-314.
(2007)
Abstract
Mouraviev, V; Sun, L; Madden, JF; Mayes, JM; Moul, JW; Polascik, TJ. Prostate cancer laterality does not predict prostate-specific antigen recurrence after radical prostatectomy. Urology. 2007;70:1141-1145.
(2007)
Abstract
Nosnik, IP; Gan, TJ; Moul, JW. Open radical retropubic prostatectomy 2007: the true minimally invasive surgery for localized prostate cancer?. Expert Review of Anticancer Therapy: an essential contribution to decision making in cancer care. 2007;7:1309-1317.
(2007)
Abstract
Robinson, MR; Moul, JW. Novel techniques for the treatment of localized prostate cancer: evidence of efficacy?. Current Urology Reports. 2007;8:203-210.
(2007)
Abstract
Scales, CD; Curtis, LH; Norris, RD; Schulman, KA; Dahm, P; Moul, JW. Relationship between body mass index and prostate cancer screening in the United States. Journal of Urology. 2007;177:493-498.
(2007)
Abstract
Scales, CD; Moul, JW; Curtis, LH; Elkin, EP; Hughes, ME; Carroll, PR; CaPSURE Investigators. Prostate cancer in the Baby Boomer generation: results from CaPSURE. Urology. 2007;70:1162-1167.
(2007)
Abstract
Sun, L; Moul, JW; Hotaling, JM; Rampersaud, E; Dahm, P; Robertson, C; Fitzsimons, N; Albala, D; Polascik, TJ. Prostate-specific antigen (PSA) and PSA velocity for prostate cancer detection in men aged <50 years. British Journal of Urology (BJU) International. 2007;99:753-757.
(2007)
Abstract
Thompson, I; Thrasher, JB; Aus, G; Burnett, AL; Canby-Hagino, ED; Cookson, MS; D'Amico, AV; Dmochowski, RR; Eton, DT; Forman, JD; Goldenberg, SL; Hernandez, J; Higano, CS; Kraus, SR; Moul, JW; Tangen, CM; AUA Prostate Cancer Clinical Guideline Update Panel. Guideline for the management of clinically localized prostate cancer: 2007 update. Journal of Urology. 2007;177:2106-2131.
(2007)
Abstract
Tseng, TY; Cancel, QV; Fesperman, SF; Kuebler, HR; Sun, L; Robertson, CN; Polascik, TJ; Moul, JW; Vieweg, J; Albala, DM; Dahm, P. The role of early adopter bias for new technologies in robot assisted laparoscopic prostatectomy. Journal of Urology. 2007;177:1318-1323.
(2007)
Abstract
Anscher, MS; Clough, R; Robertson, CN; Prosnitz, LR; Dahm, P; Walther, P; Donatucci, CF; Albala, DM; Febbo, P; George, DJ; Sun, L; Moul, JW. Timing and patterns of recurrences and deaths from prostate cancer following adjuvant pelvic radiotherapy for pathologic stage T3/4 adenocarcinoma of the prostate. Prostate Cancer and Prostatic Diseases. 2006;9:254-260.
(2006)
Abstract
Efstathiou, JA; Chen, MH; Catalona, WJ; McLeod, DG; Carroll, PR; Moul, JW; Roehl, KA; D'Amico, AV. Prostate-specific antigen-based serial screening may decrease prostate cancer-specific mortality. Urology. 2006;68:342-347.
(2006)
Abstract
Freedland, SJ; Krupski, TL; Moul, JW. Update on outcomes research databases in prostate cancer 2006. Current Opinion in Urology. 2006;16:168-172.
(2006)
Abstract
Lee, WR; Moul, JW. Can prostate-specific antigen nadir predict prostate cancer outcomes following radiotherapy?. Nature Clinical Practice Oncology. 2006;3:534-535.
(2006)
Abstract
Merseburger, AS; Hennenlotter, J; Simon, P; Müller, CC; Kühs, U; Knüchel-Clarke, R; Moul, JW; Stenzl, A; Kuczyk, MA. Activation of the PKB/Akt pathway in histological benign prostatic tissue adjacent to the primary malignant lesions. Oncology Reports: an international journal devoted to fundamental and applied research in oncology. 2006;16:79-83.
(2006)
Abstract
Moul, JW. Treatment of PSA only recurrence of prostate cancer after prior local therapy. Current Pharmaceutical Design. 2006;12:785-798.
(2006)
Abstract
Moul, JW; Ward, JF. Management of the patient with a rising PSA alone. Hematology / Oncology Clinics of North America. 2006;20:897-908.
(2006)
Abstract
Scales, CD; Curtis, LH; Norris, RD; Schulman, KA; Albala, DM; Moul, JW. Prostate specific antigen testing in men older than 75 years in the United States. Journal of Urology. 2006;176:511-514.
(2006)
Abstract
Sun, M; Srikantan, V; Ma, L; Li, J; Zhang, W; Petrovics, G; Makarem, M; Strovel, JW; Horrigan, SG; Augustus, M; Sesterhenn, IA; Moul, JW; Chandrasekharappa, S; Zou, Z; Srivastava, S. Characterization of frequently deleted 6q locus in prostate cancer. DNA and Cell Biology. 2006;25:597-607.
(2006)
Abstract
Tseng, TY; Sevilla, DW; Moul, JW; Maloney, KE. Prostatic carcinosarcoma 15 years after combined external beam radiation and brachytherapy for prostatic adenocarcinoma: a case report. Prostate Cancer and Prostatic Diseases. 2006;9:195-197.
(2006)
Abstract
Xu, LL; Sun, C; Petrovics, G; Makarem, M; Furusato, B; Zhang, W; Sesterhenn, IA; McLeod, DG; Sun, L; Moul, JW; Srivastava, S. Quantitative expression profile of PSGR in prostate cancer. Prostate Cancer and Prostatic Diseases. 2006;9:56-61.
(2006)
Abstract
Bañez, LL; Srivastava, S; Moul, JW. Proteomics in prostate cancer. Current Opinion in Urology. 2005;15:151-156.
(2005)
Abstract
Brassell, SA; Kao, TC; Sun, L; Moul, JW. Prostate-specific antigen versus prostate-specific antigen density as predictor of tumor volume, margin status, pathologic stage, and biochemical recurrence of prostate cancer. Urology. 2005;66:1229-1233.
(2005)
Abstract
Cooperberg, MR; Moul, JW; Carroll, PR. The changing face of prostate cancer. Journal of Clinical Oncology. 2005;23:8146-8151.
(2005)
Abstract
Dahm, P; Yang, BK; Salmen, CR; Moul, JW; Gan, TJ. Radical perineal prostatectomy for the treatment of localized prostate cancer in morbidly obese patients. Journal of Urology. 2005;174:131-134.
(2005)
Abstract
Gu, Y; Kim, KH; Ko, D; Srivastava, S; Moul, JW; McLeod, DG; Rhim, JS. Androgen and androgen receptor antagonist responsive primary African-American benign prostate epithelial cell line. Anticancer Research: international journal of cancer research and treatment. 2005;25:1-8.
(2005)
Abstract
Moul, JW. Screening for prostate cancer in military populations. Military Medicine: international journal of AMSUS. 2005;170:905-914.
(2005)
Abstract
Moul, JW; Saad, F. Low-risk prostate cancer patient: active treatment. Canadian Journal of Urology. 2005;12 Suppl 2:25-27.
(2005)
Abstract
Moul, JW; Zlotta, AR. Hormonal therapy options for prostate-specific antigen-only recurrence of prostate cancer after previous local therapy. British Journal of Urology (BJU) International. 2005;95:285-290.
(2005)
Abstract
Petrovics, G; Liu, A; Shaheduzzaman, S; Furusato, B; Sun, C; Chen, Y; Nau, M; Ravindranath, L; Chen, Y; Dobi, A; Srikantan, V; Sesterhenn, IA; McLeod, DG; Vahey, M; Moul, JW; Srivastava, S. Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome. Oncogene. 2005;24:3847-3852.
(2005)
Abstract
Semmes, OJ; Feng, Z; Adam, BL; Banez, LL; Bigbee, WL; Campos, D; Cazares, LH; Chan, DW; Grizzle, WE; Izbicka, E; Kagan, J; Malik, G; McLerran, D; Moul, JW; Partin, A; Prasanna, P; Rosenzweig, J; Sokoll, LJ; Srivastava, S; Srivastava, S; Thompson, I; Welsh, MJ; White, N; Winget, M; Yasui, Y; Zhang, Z; Zhu, L. Evaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer: I. Assessment of platform reproducibility. Clinical Chemistry (Washington, DC): international journal of molecular diagnostics and laboratory medicine. 2005;51:102-112.
(2005)
Abstract
Stewart, AJ; Scher, HI; Chen, MH; McLeod, DG; Carroll, PR; Moul, JW; D'Amico, AV. Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure. Journal of Clinical Oncology. 2005;23:6556-6560.
(2005)
Abstract
Ward, JF; Moul, JW. Biochemical recurrence after definitive prostate cancer therapy. Part I: defining and localizing biochemical recurrence of prostate cancer. Current Opinion in Urology. 2005;15:181-186.
(2005)
Abstract
Ward, JF; Moul, JW. Biochemical recurrence after definitive prostate cancer therapy. Part II: treatment strategies for biochemical recurrence of prostate cancer. Current Opinion in Urology. 2005;15:187-195.
(2005)
Abstract
Ward, JF; Moul, JW. Rising prostate-specific antigen after primary prostate cancer therapy. Nature Reviews: Urology. 2005;2:174-182.
(2005)
Abstract
Ward, JF; Moul, JW. Treating the biochemical recurrence of prostate cancer after definitive primary therapy. Clinical Prostate Cancer. 2005;4:38-44.
(2005)
Abstract
Zhou, P; Chen, MH; McLeod, D; Carroll, PR; Moul, JW; D'Amico, AV. Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy. Journal of Clinical Oncology. 2005;23:6992-6998.
(2005)
Abstract
